Full-Time

Sr. Director

GI Oncology

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology company specializing in genetic testing

No salary listed

Senior, Expert

Company Historically Provides H1B Sponsorship

United States

In Person

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Sales
Requirements
  • Bachelor’s degree or equivalent; MBA preferred.
  • Minimum 10 years of successful sales experience, preferably in oncology, laboratory, or the diagnostic industry, with either 5 years of leadership experience or at least 5 years of Strategic Accounts focus.
  • Experience with major account management sales processes such as Miller Heiman, SPIN, or similar methodologies preferred.
  • Proven track record of managing large, complex accounts and driving sustained revenue growth.
  • Proven ability to collaborate with cross-functional teams, including Customer Service, Marketing, Product, Medical, UX, IT, Analytics, Legal, and Compliance.
  • Strong business acumen with expertise in Health System/Provider KPIs, regulatory frameworks (CLIA, CAP, CMS), reimbursement structures (DRG, OPPS, PAMA, state regulations), and compliance requirements (Stark, Anti-Kickback, Antitrust).
  • Deep understanding of customer external influencers and market trends.
  • Ability to thrive in a fast-paced, dynamic environment while managing multiple priorities effectively.
  • Proven success in developing new markets, launching new products, and driving rapid revenue growth.
  • Requires 75% travel.
Responsibilities
  • Develop National KOL’s for podium presence/advocacy and implement a comprehensive Esophageal / Pancreatic Cancer strategy for key accounts to achieve access to Natera tests, drive Oncology unit volume and revenue growth through standardization protocols, establishing reflex testing pathways, contracting and account retention.
  • Build and maintain strong relationships with clinical influencers in Health Systems and cooperative groups to identify growth opportunities and provide Natera’s solutions to key customer challenges.
  • Partner with the Directors of Strategic Accounts (DSAs) to ensure exceptional service delivery and alignment with key Oncology Service Line stakeholders, including hospital and cancer center leadership, C-suite executives, pathologists, residency and fellowship program directors, oncology educators, grand rounds and journal clubs, and laboratory directors overseeing send-out testing.
  • Collaborate with field sales teams, medical sales liaisons, medical directors to drive oncology test pull-thru, client success and improve offerings based on client feedback and customer insight.
  • Analyze market trends and competitive landscape to identify new opportunities for account growth.
  • Work with DSA’s and Field Sales to monitor account performance metrics and prepare regular business reviews for both the customer and Natera’s senior management, highlighting successes and areas for improvement.
  • Foster a culture of continuous improvement within the account management team, promoting best practices and innovative approaches to customer challenges, problems and issues.
Desired Qualifications
  • Experience in developing and leading high-performing teams, preferred.
  • Market knowledge and experience in Women’s Health preferred.

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and monitor transplanted organ health. Natera also offers tests for family planning and prenatal screening, including the Panorama NIPT, which has conducted over 2 million tests. The company generates revenue through testing kits and services, often reimbursed by insurance, and provides genetic counseling for personalized patient support.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Integration of AI could enhance Natera's genetic testing capabilities.
  • Growing demand for personalized medicine supports Natera's mission.
  • Telehealth expansion facilitates remote genetic counseling, boosting service accessibility.

What critics are saying

  • Increased competition from companies like Lantheus Holdings.
  • $9.9 million investment in Austin may strain financial flexibility.
  • Rapid technological advancements require continuous innovation to stay competitive.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for diverse medical needs.
  • Their Signatera test offers personalized ctDNA analysis for cancer patients.
  • Panorama NIPT has achieved over 2 million tests, showcasing its reliability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
ISHLT
Jul 3rd, 2025
Expanding Our Understanding of dd-cfDNA in Providing Lung Transplant Personalized Care

At their industry symposium at ISHLT2025, Natera provided a brief history of dd-cfDNA in lung transplantation rejection monitoring, highlighting the power of the negative to rule out rejection.

PRWeb
May 30th, 2025
The Melanoma Research Foundation To Host The Denver Miles For Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT. We are excited to share that Kyle Speller, PA Announcer for the Denver Nuggets, will be returning as our emcee on event day! We're also excited to welcome back local sponsor, Cara Mia Dermatology, who will be providing free on-site skin screenings—helping our community stay sun-safe while supporting a great cause.DENVER, May 29, 2025 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT

Intelligence360
May 15th, 2025
Natera To Spend $9.9 Million To Occupy 30,000 Square Feet Of Space In Austin Texas.

Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas. Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas.Austin, Texas — According to state and local development sources, Natera plans to invest $9,900,000.00 to build out 30,000 square feet of new space in Austin. The company plans to occupy the new space at 13011A McCallen Pass in Austin, on or about January 1, 2026. According to the company website Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, womens health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment

TXBN
Apr 24th, 2025
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera(TM) Genome MRD Test

Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.

Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).